Achieve Life Sciences Inc. (ACHV)
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences Q1 Earnings Call Highlights
Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027.
Achieve Life Sciences: The Recent Sell Off Skews The Outcomes
Achieve Life Sciences is rated Buy for risk-tolerant investors after a sharp sell-off tied to FDA manufacturing concerns. Cytisinicline demonstrates strong efficacy and a superior safety profile versus Chantix, supporting blockbuster potential in smoking cessation. Manufacturing issues prompted a supplier switch to Adare Pharma; FDA approval probability is estimated at 35% on the first try, rising to 70% if resubmitted.
Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation
Achieve Life Sciences remains a 'Buy' as cytisinicline's NDA for smoking cessation is under FDA review with a PDUFA date of June 20, 2026. ACHV exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H 2027 commercial launch if approved. The company plans to initiate the phase 3 ORCA-V2 trial for vaping cessation in 1H 2026, targeting a large, underserved market segment.
Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $4.24 and traded as high as $4.37. Achieve Life Sciences shares last traded at $4.14, with a volume of 530,131 shares changing hands. Analyst Ratings Changes
Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch
Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA. Cytisinicline's α4β2 partial agonism aims to reduce cravings and blunt nicotine reward. In fact, the most promising aspect of cytisinicline was that its Phase 3 ORCA trials showed strong quit-rate deltas versus placebo.
Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV's market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Cindy Jacobs - Former President & Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark K. Oki - Chief Financial Officer Nicole Jones - Corporate Participant Richard A.
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation
ACHV's cytisinicline shows best-in-class efficacy and safety for smoking cessation, supported by strong clinical data and recent NDA submission. The target market is large, with millions seeking smoking cessation annually. Recent financing extends ACHV's cash runway through FDA approval, but further capital will be needed for commercialization.
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk
Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials. The company addresses a significant unmet need in tobacco addiction, with cytisinicline showing promising efficacy and safety data compared to existing therapies. While FDA approval may be difficult, the low valuation and high potential peak sales provide a decent risk/reward profile.
Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Nicole Jones - Investor Relations Rick Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Mark Oki - Chief Financial Officer Jaime Xinos - Chief Commercial Officer Conference Call Participants Gary Nachman - Raymond James Justin Walsh - Jones Trading John Vandermosten - Zacks Investment Research Operator Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings Conference Call and Webcast.
